Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) | Interleukin Related interleukin-related.com

Product Name :
Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech)

Search keywords :
Anti-CD20 Antibody

drugId :
null

Target Vo:
B-lymphocyte antigen CD20

Target Vo Short Name :
CD20

Moa_Name:
Antibody-dependent cell-mediated cytotoxicity (ADCC) effects

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Zhejiang Hisun Pharmaceutical Co Ltd

Active Company_Name :
Beijing Mabworks Biotech Co Ltd

Active Indication_Name:
Lymphoma, Large B-Cell, Diffuse

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 3 Clinical

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
ERCC1 (YP6027) Mouse mAb Epigenetic Reader Domain
Panitumumab web
Acetyl-Histone H3 (Lys14) Antibody: Acetyl-Histone H3 (Lys14) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 15 kDa, targeting to Acetyl-Histone H3 (Lys14). It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Rat.

Author: Interleukin Related

Related Posts